Antibody-drug conjugates are a new kind of targeted treatment for multiple myeloma. They deliver powerful cancer-killing drugs straight to myeloma cells, and they help your own immune system attack ...
Antibody-drug conjugates are rapidly expanding cancer therapies, with 19 approved globally and many more in development, but ...
Parabilis is set to receive $125m, including a $50m upfront payment and a $75m investment, subject to agreed conditions.
The field of oncology has seen transformative advancements with the development of antibody-drug conjugates (ADCs), which are rapidly revolutionizing the treatment of several cancer types, including ...
Next Generation Drug Conjugates Market · GlobeNewswire Inc. Dublin, May 18, 2026 (GLOBE NEWSWIRE) -- The "Next Generation Drug Conjugates Market by Product, Type, Target Ligand, ...
Developers extend the logic of ADCs and antibody conjugation, enabling highly selective therapeutics based on PROTACs, ...
(MENAFN- GlobeNewsWire - Nasdaq) Key market opportunities for bispecific antibody drug conjugates (BsADCs) include their potential to revolutionize cancer treatment through enhanced tumor selectivity ...
The conjugate space is evolving fast - moving beyond traditional ADCs into new formats like degrader-conjugates, oligonucleotide conjugates, bispecific ADCs, and more. The 4 th Novel Conjugates Summit ...
Parabilis Medicines, the developer of drugs and antibody-drug conjugates targeting historically undruggable protein targets ...
Improved Linker and Payload Selection: The selection of suitable linkers and cytotoxic payloads greatly impacts ADC stability, efficacy, and safety. Next-generation ADCs aim to employ novel linkers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results